INBX Should I Buy
An analysis of Inhibrx Biosciences Inc (INBX) suggests it is not a strong buy for long-term investors due to a lack of positive financial performance, significant trading trends, and recent catalysts. Financials for Q4 2025 showed a 100% drop in revenue, a 31.4% decline in net income, and a 31.72% drop in EPS. Technical indicators show weak bullish momentum and indecision, with no recent analyst ratings available.
Discipline and Rules-Based Execution in INBX Response
This article provides a detailed analysis of Inhibrx Biosciences Inc (INBX) using AI models to generate trading strategies and signal analyses. It highlights positive near-term sentiment while noting potential mid-term weakness within a long-term strength context, identifying elevated downside risk. The report offers specific position, momentum breakout, and risk hedging strategies, alongside multi-timeframe support and resistance levels.
Inhibrx Biosciences partners with Sarcoma Alliance to advance patient education resources
Inhibrx Biosciences has formed a partnership with the Sarcoma Alliance to enhance educational resources and support for the sarcoma patient community. This collaboration underscores Inhibrx's commitment to improving information and outreach initiatives for individuals affected by this rare cancer. The company also continues to engage in clinical research, recently showcasing its INBRX-106 research for head and neck cancers.
Inhibrx Biosciences FY25 Review: Catalyst-Driven Hold Ahead Of Key 2026 Data (INBX)
Inhibrx Biosciences (INBX) reported a significant net loss of $140.1 million in FY25, reflecting a restructuring year after the Sanofi transaction. The company's valuation is heavily dependent on the clinical success of its lead candidates, ozekibart and INBRX-106, with ozekibart having shown promising results in chondrosarcoma. Despite this, the author maintains a Hold rating as the current valuation already incorporates potential upside from upcoming 2026 clinical and regulatory milestones.
Inhibrx Biosciences (INBX) Expected to Announce Earnings on Tuesday
Inhibrx Biosciences (NASDAQ:INBX) is anticipated to announce its Q4 2025 earnings before market open on Tuesday, March 31st, with analysts forecasting a loss of ($2.08) per share. The company, which recently reported a loss of ($2.11) per share for the prior quarter, will host an earnings call on April 3, 2026, at 5:00 PM ET. Currently, INBX has a "Reduce" consensus rating from analysts, and institutional investors hold approximately 82.5% of its stock.
Inhibrx Biosciences Reports 2025 Financial Results
Inhibrx Biosciences reported its 2025 financial results, showing $124.2 million in cash and cash equivalents, a net loss of $140.1 million, and an operating loss of $135 million. The company significantly reduced R&D expenses to $113.1 million from $203.7 million in 2024. Looking ahead, Inhibrx plans to submit a Biologics License Application to the FDA in Q2 2026 and release clinical trial data for ozekibart and INBRX-106, aiming to improve its market position.
Inhibrx Biosciences Reports Q4 Earnings Miss
Inhibrx Biosciences reported a Q4 GAAP EPS of -$2.11, missing expectations by $0.03, highlighting ongoing profitability challenges. Despite holding $124.2 million in cash and securing a $75 million loan, concerns remain regarding fund utilization and long-term financing. The company is, however, actively pursuing R&D in treatments for chondrosarcoma and other indications, with future advancements potentially offering new growth opportunities.
INBX SEC Filings - Inhibrx Biosciences Inc 10-K, 10-Q, 8-K Forms
This article provides a comprehensive overview of Inhibrx Biosciences Inc.'s (INBX) SEC filings, including 10-K, 10-Q, and 8-K forms. It details the company's clinical-stage pipeline, financial position, and material events such as clinical trial results and corporate structural changes. The platform also offers AI-powered summaries to help investors quickly parse regulatory documents.
Inhibrx Inc stock surges on Q4 2025 earnings and key 2026 pipeline milestones
Inhibrx Inc's stock surged after reporting Q4 and full-year 2025 financial results, which included a net loss but significant reductions in R&D and G&A expenses. The company also secured new debt funding and announced upcoming data readouts for its oncology candidates, ozekibart and INBRX-106, with a BLA submission for ozekibart planned for early Q2 2026. This strategic pipeline focus and cost discipline led to a 9.6% gain in stock price, attracting investor optimism for its 2026 milestones.
Inhibrx Biosciences (NASDAQ:INBX) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS
Inhibrx Biosciences (NASDAQ:INBX) released its quarterly earnings, reporting an EPS of ($2.11), missing analyst expectations by $0.03. Following the announcement, the stock fell by $3.82 to $64.87 on Thursday. Wall Street analysts currently have a "Reduce" rating on the stock, with institutional investors holding a significant 82.46% of shares.
Inhibrx Biosciences 10-K: $1.3M revenue, EPS $(9.04)
Inhibrx Biosciences reported $1.3 million in revenue, largely from a Scithera license fee, and a net loss per share of $(9.04) for the year, primarily due to investments in clinical programs. Despite a significant net loss, the company improved its loss from operations and its cash reserves of $124.2 million are expected to sustain operations for at least 12 months. Key business highlights include advancing two clinical-stage programs, meeting the primary endpoint in a chondrosarcoma trial, and completing its separation from its former parent company.
Inhibrx Biosciences Q4 net loss narrows as expenses fall
Inhibrx Biosciences reported a narrower net loss for the fourth quarter, attributed to a decrease in expenses. The company's financial update indicates an improvement in its financial performance compared to previous periods.
Inhibrx Biosciences (NASDAQ: INBX) details 2025 loss and 2026 trial plans
Inhibrx Biosciences reported a net loss of $140.1 million in 2025, a significant decline from the $1.7 billion net income in 2024, which was boosted by a one-time gain from the INBRX-101 transaction. The company reduced its R&D and G&A expenses and ended the year with $124.2 million in cash, supplemented by a recent $75 million loan. Looking ahead, Inhibrx plans to submit a BLA for ozekibart in early Q2 2026 and expects multiple data readouts for ozekibart and INBRX-106 throughout the year.
Slotnik Capital LLC Sells 142,770 Shares of Inhibrx Biosciences, Inc. $INBX
Slotnik Capital LLC significantly reduced its stake in Inhibrx Biosciences, Inc. by selling 142,770 shares, cutting its holding by 77.5% to 41,401 shares. Despite this sell-off, other institutional investors like BNP Paribas, Bank of America, Invesco, and Arrowstreet Capital have either increased or initiated positions in INBX, with institutional ownership standing at approximately 82.46%. Inhibrx Biosciences (NASDAQ:INBX) trades around $68.74, but analysts currently have a consensus "Reduce" rating on the stock.
(INBX) Movement Within Algorithmic Entry Frameworks
The article focuses on Inhibrx Biosciences Inc (INBX) within algorithmic entry frameworks, highlighting divergent sentiment across all time horizons, suggesting choppy conditions. It identifies that support is being tested and presents an exceptional 87.9:1 risk-reward setup targeting a 25.7% gain against a 0.3% risk. Three distinct AI-generated trading strategies are provided: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, along with a multi-timeframe signal analysis.
Inhibrx Biosciences (INBX) to Release Quarterly Earnings on Monday
Inhibrx Biosciences (NASDAQ: INBX) is scheduled to release its Q4 2025 earnings before the market opens on Monday, March 16th, with analysts forecasting a loss of ($2.08) per share. The company's stock opened at $69.18, with a market capitalization of $1.01 billion, and has an average analyst rating of "Reduce." Institutional ownership of the stock is high at 82.46%.
Ewing sarcoma study of ozekibart takes stage at rare cancer congress
Inhibrx Biosciences (Nasdaq: INBX) announced it will present clinical data at the ESMO Sarcoma and Rare Cancers Congress in Lugano, Switzerland, from March 12-14, 2026. The presentation will detail Phase 1 study results for their tetravalent DR5 agonist ozekibart (INBRX-109) in combination with irinotecan and temozolomide for adolescents and adults with Ewing sarcoma. The company also provided an overview of its corporate structure and pipeline of novel biologic therapeutic candidates.
Inhibrx Announces Participation in Upcoming Scientific Conference
Inhibrx Biosciences, Inc. (Nasdaq: INBX) announced its participation in the upcoming ESMO Sarcoma and Rare Cancers Congress. The company will present findings from its Phase 1 study of the tetravalent Death Receptor 5 (DR5) agonist ozekibart (INBRX-109) in combination with irinotecan and temozolomide for adolescents and adults with Ewing Sarcoma. The presentation is scheduled for March 12, 2026, in Lugano, Switzerland.
Inhibrx Announces Participation in Upcoming Scientific Conference
Inhibrx Biosciences, Inc. (Nasdaq: INBX) announced its participation in the ESMO Sarcoma and Rare Cancers Congress, scheduled for March 12-14, 2026, in Lugano, Switzerland. The company will present results from a Phase 1 study of ozekibart (INBRX-109), a tetravalent Death Receptor 5 (DR5) agonist, combined with chemotherapy for Ewing Sarcoma patients. This presentation highlights Inhibrx's ongoing clinical development of novel biologic therapeutic candidates.
Inhibrx Announces Participation in Upcoming Scientific Conference
Inhibrx Biosciences, Inc. announced its participation in the upcoming ESMO Sarcoma and Rare Cancers Congress. The company will present findings from its Phase 1 study of ozekibart combined with irinotecan and temozolomide for Ewing Sarcoma. The presentation will take place on March 12, 2026, in Lugano, Switzerland.
How (INBX) Movements Inform Risk Allocation Models
This article analyzes Inhibrx Biosciences Inc (INBX) using AI models, identifying weak near and mid-term sentiment but a strong long-term outlook. It presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, emphasizing risk management and offering real-time signals with an exceptional risk-reward setup.
Inhibrx Announces Participation in Upcoming Scientific Conference
Inhibrx Biosciences, Inc. (Nasdaq: INBX) announced its participation in the upcoming ESMO Sarcoma and Rare Cancers Congress from March 12-14, 2026, in Lugano, Switzerland. The company will present findings from a Phase 1 study of ozekibart (INBRX-109) in combination with irinotecan and temozolomide for Ewing Sarcoma. The presentation details will be available on Inhibrx's investor website.
INBX Stock News Today | Earnings, Events & Price Alerts
This article provides news and event updates for Inhibrx (INBX) stock. Key updates include progress in clinical trials for INBRX-106 and ozekibart, significant borrowing rate hikes among liquid assets, and positive topline results from the ChonDRAgon study for ozekibart in chondrosarcoma. The company anticipates major milestones in the coming year and future data maturity for its drug programs.
INBX Technical Analysis & ETF Price Forecast
The article provides a technical analysis of Inhibrx Biosciences Inc (INBX), noting its current stock price and various moving averages. It indicates a "Neutral" technical sentiment based on its proprietary analysis, despite some buy signals from simple moving averages. Key indicators like RSI, MACD, and support/resistance levels are mentioned, though specific values for many are listed as "-".
Inhibrx Biosciences Highlights 2026 Pipeline and Strategy
Inhibrx Biosciences recently released an investor presentation detailing its updated corporate strategy, financial standing, and upcoming catalysts for 2026. The company intends to maximize shareholder value by prioritizing the readout of INBRX-106 data and exploring potential future transactions for ozekibart, strategically pausing immediate sale or spin-off options until INBRX-106 Phase 2 data clarifies valuation. Key milestones for 2026 include data readouts for Ewing sarcoma and colorectal cancer, a planned BLA submission and potential approval for ozekibart, and regulatory discussions for accelerated pathways in other indications.
INBX Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Inhibrx Biosciences Inc (INBX), including its income statement, balance sheet, and cash flow statement. For fiscal year 2024, the company reported a significant decrease in revenue to $200K but a substantial increase in net income to $1.7B, alongside a high return on equity. The analysis highlights mixed financial health signals, with strong leverage and liquidity but concerns regarding profitability and interest coverage.
Trading Systems Reacting to (INBX) Volatility
This article analyzes Inhibrx Biosciences Inc (INBX) volatility using AI models, highlighting weak near-term sentiment despite strong mid and long-term outlooks. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels for different risk profiles. The analysis also provides multi-timeframe signal analysis, including support and resistance levels.
Inhibrx Biosciences, Inc. $INBX Shares Sold by Credit Industriel ET Commercial
Credit Industriel ET Commercial significantly reduced its stake in Inhibrx Biosciences (NASDAQ:INBX) by 54.9% in the third quarter, now holding 28,958 shares valued at approximately $975,000. Despite the company beating Q3 EPS consensus, analysts maintain a "Reduce" average rating on the stock, with shares recently down 7.7% and opening at $75.80. Other institutional investors have shown mixed activity, with some increasing and others reducing their positions in INBX.
Inhibrx Biosciences (NASDAQ:INBX) Shares Down 6.8% - Here's What Happened
Inhibrx Biosciences (NASDAQ:INBX) saw its shares drop by 6.8% on Friday, trading as low as $76.01 with a significantly reduced volume of 97,486 shares. The company, a clinical-stage biotech developing protein therapeutics, has a consensus "Reduce" rating from analysts, with a negative P/E ratio but strong liquidity. Institutional investors have recently made adjustments to their holdings in the stock.
Morgan Stanley discloses 7.9% Inhibrx (INBX) stake in 13G filing
Morgan Stanley and its affiliate Morgan Stanley Capital Services LLC have disclosed a 7.9% beneficial ownership stake in Inhibrx Biosciences, Inc. (INBX) common stock through a Schedule 13G filing. The filing indicates that Morgan Stanley beneficially owns 1,155,416 shares, while Morgan Stanley Capital Services LLC owns 918,011 shares, representing 6.3%. This is a passive investment, meaning the shares were acquired in the ordinary course of business and not with the intention of influencing or changing control of Inhibrx Biosciences.
How Inhibrx Biosciences Inc Com (INBX) Affects Rotational Strategy Timing
This article analyzes Inhibrx Biosciences Inc Com (INBX) and its impact on rotational strategy timing, highlighting strong sentiment across all time horizons. It details institutional trading strategies, including long, momentum breakout, and risk hedging, with specific entry points, targets, and stop losses. The analysis also provides multi-timeframe signal strengths with support and resistance levels.
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 10.2% - Still a Buy?
Shares of Inhibrx Biosciences (INBX) surged 10.2% to $84.05 on Monday, though this occurred on low trading volume. Despite beating quarterly EPS estimates, the company holds an average analyst rating of "Reduce," with two Holds and one Sell. Inhibrx maintains strong liquidity and significant institutional ownership, but analysts forecast negative EPS for the current fiscal year.
Commit To Purchase Inhibrx Biosciences At $50, Earn 16.7% Annualized Using Options
This article discusses an options strategy for investors interested in Inhibrx Biosciences Inc (INBX) but cautious about its current market price. By selling a January 2027 put option at a $50 strike price, investors could earn an annualized return of 16.7%. This strategy offers a substantial premium if the stock does not fall significantly, but obligates the investor to purchase shares at $50 if the option is exercised due to a price drop.
Inhibrx Biosciences Reports Promising Q3 2025 Results
The provided content is empty, so a summary cannot be generated.
Responsive Playbooks and the INBX Inflection
This article analyzes Inhibrx Biosciences Inc (INBX) with a focus on its current weak near and mid-term sentiment, contrasting it with a strong long-term outlook. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, highlighting a significant 106.9:1 risk-reward setup targeting a 30.4% gain.
Short Interest in Inhibrx Biosciences, Inc. (NASDAQ:INBX) Rises By 63.1%
Short interest in Inhibrx Biosciences, Inc. (NASDAQ:INBX) significantly increased by 63.1% in December, reaching 1,712,725 shares. This represents about 11.8% of the company's shares being short sold, with a days-to-cover ratio of 6.2 days. Despite beating quarterly EPS estimates, the stock's market performance showed a 5.4% decline, and Wall Street analysts currently hold a "Reduce" consensus rating.
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 6.5% - What's Next?
Inhibrx Biosciences' (NASDAQ:INBX) stock fell by 6.5% to $71.04 in mid-day trading on Tuesday, with trading volume significantly lower than average. Analyst sentiment remains weak for the company, holding a consensus "Reduce" rating. Despite a negative P/E ratio, the company recently beat EPS estimates, and institutional investors own a substantial 82.46% of its shares.
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Sees Large Decline in Short Interest
Inhibrx Biosciences, Inc. (NASDAQ:INBX) experienced a significant 20.5% decline in short interest during December, totaling 1,049,942 shares as of December 15th. This reduction brings the days-to-cover ratio to 5.3 days, with 7.2% of the company's shares currently short sold. Additionally, a major shareholder, Global Investors Lp Viking, sold a substantial portion of its holdings, and institutional investors now hold 82.46% of the stock.
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts
Inhibrx Biosciences Inc. is progressing its primary oncology programs, INBRX-106 and ozekibart (INBRX-109), both designed to activate the immune system and target tumor cell death. The company expects multiple data readouts in 2026 for its Phase 2/3 trial of INBRX-106 in combination with Keytruda for head and neck squamous cell carcinoma and non-small cell lung cancer, as well as progression-free survival data for ozekibart in colorectal cancer. Enrollment for these trials is nearing completion, with results anticipated to assess sustained clinical benefit.
How (INBX) Movements Inform Risk Allocation Models
This article analyzes Inhibrx Biosciences Inc (INBX) stock movements, highlighting a weak near-term sentiment but strong long-term outlook. It presents three AI-generated trading strategies tailored for different risk profiles, along with multi-timeframe signal analysis and key levels. The piece emphasizes the importance of understanding INBX movements for risk allocation models.
Inhibrx Biosciences (INBX): Assessing Valuation After New Oncology Pipeline and FDA Milestone Updates
Inhibrx Biosciences (INBX) has updated investors on its oncology pipeline, with progress in INBRX-106 combo trials and ozekibart studies, leading to significant share price appreciation. Despite strong market momentum and a 498.63% one-year total shareholder return, the company's valuation presents an aggressive premium with a price-to-book ratio of 32.8x. This suggests investors are heavily anticipating future pipeline success rather than current fundamentals, contrasting sharply with industry averages.
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Inhibrx Biosciences announced updates on its INBRX-106 and ozekibart (INBRX-109) programs. The company expects to complete enrollment for the randomized Phase 2 portion of the INBRX-106 clinical trial for HNSCC in Q1 2026 and anticipates mature data for both HNSCC and NSCLC in H2 2026. For ozekibart, Inhibrx completed enrollment for colorectal cancer expansion cohorts and expects to complete enrollment for Ewing sarcoma in Q2 2026, with plans to discuss accelerated approval with the FDA in H2 2026 if trends continue.
Inhibrx Biosciences (INBX): Assessing Valuation After New Oncology Pipeline and FDA Milestone Updates
This article assesses Inhibrx Biosciences (INBX) valuation after recent oncology pipeline updates, including progress in INBRX-106 combo trials and ozekibart studies. Despite a significant year-to-date share price return of 444.85%, the company's price-to-book ratio of 32.8x suggests an aggressive valuation, far exceeding industry averages, and implying that the market is heavily anticipating future pipeline success rather than current fundamentals. The analysis highlights that while the company shows bullish momentum, its reliance on early-stage assets and ongoing losses present considerable risks.
Citizens reiterates Market Perform rating on Inhibrx Biosciences stock citing limited data disclosures
Citizens has reiterated its Market Perform rating on Inhibrx Biosciences (NASDAQ:INBX) due to concerns over limited data disclosures and lack of management communication, despite the stock's significant gains over the past year. The firm questions the durability and strength of treatment responses in its clinical programs, particularly for INBRX-109, with mature progression-free survival data expected in Q2 2026. This assessment comes amidst other positive developments, including positive topline results for ozekibart and progress in the INBRX-106 clinical trial.
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Inhibrx Biosciences, Inc. announced updates on its INBRX-106 and ozekibart (INBRX-109) programs. The company has recruited 46 of 60 patients for the Phase 2 portion of the INBRX-106 trial for HNSCC, expecting to complete enrollment in Q1 2026, and completed enrollment for its NSCLC trial in November 2025. For ozekibart, enrollment for colorectal cancer patients was completed in late October 2025, and enrollment for Ewing sarcoma is expected to complete in Q2 2026, with plans to discuss accelerated approval with the FDA in H2 2026.
Inhibrx Biosciences Provides Updates on Clinical Trials
Inhibrx Biosciences announced updates on its INBRX-106 and ozekibart clinical trials on December 16, 2025. The INBRX-106 Phase 2 trial for HNSCC has recruited 46 of 60 patients, and the NSCLC trial with Keytruda completed enrollment of 34 patients, with efficacy data expected in late 2026. Separately, the ozekibart trial for colorectal cancer finished enrolling 44 patients, and an FDA meeting for the Ewing sarcoma trial is scheduled for late 2026.
Understanding Momentum Shifts in (INBX)
This article analyzes momentum shifts for Inhibrx Biosciences Inc Com (NASDAQ: INBX), noting weak near-term sentiment but prevailing positive sentiment overall. It provides AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging strategies. The analysis highlights key support and resistance levels across near-term, mid-term, and long-term horizons.
Mark Asset Management LP Buys Shares of 17,000 Inhibrx Biosciences, Inc. $INBX
Mark Asset Management LP has acquired a new stake of 17,000 shares in Inhibrx Biosciences, Inc. (NASDAQ:INBX) valued at approximately $243,000, contributing to the 82.46% institutional ownership of the company. Despite weak analyst sentiment with a consensus "Reduce" rating, the company recently beat EPS expectations. The stock shows a market capitalization of $1.20 billion and has experienced significant price fluctuations over the past 12 months.
Inhibrx Biosciences advances sarcoma research with ozekibart trial results
Inhibrx Biosciences has announced significant developments in their sarcoma research, specifically concerning the ozekibart (INBRX 109) trial for chondrosarcoma. This advancement underlines the company's continuous efforts in oncology, building on previous successes in glioblastoma treatment. Inhibrx is further cementing its commitment to rare cancer therapies through strategic sponsorships and community engagement.
Inhibrx Biosciences, Inc. $INBX Shares Acquired by Kennedy Capital Management LLC
Kennedy Capital Management LLC increased its holding in Inhibrx Biosciences (NASDAQ:INBX) by 7.5% in the second quarter of 2025, acquiring 12,342 additional shares for a total of 177,318 shares valued at $2.53 million. Despite this, the stock carries mixed-to-negative analyst ratings ("Reduce" average) and has seen a major insider sell-off of 350,000 shares by Global Investors LP Viking. The company reports a negative trailing P/E of -8.93 but strong financial health with a quick ratio of 4.49, and its stock is currently trading near its 52-week high.
